a client in need of long-term anti-inflammatory medication has been tried on nsaid and nsaid combination therapy with anti-ulcer medications, but continues to have recurring gi ulcerations. the treating physician discusses the possibility of switching to a different nsaid known as celecoxib (celebrex), a cyclooxygenase-2 (cox-2) inhibitor. what is the health care practitioner aware of when educating the client about the rationale for switching medications?